This amidated peptide potently and teversibly inhibits Cav2.2/CACNA1B. Steady-state inactivation is enhanced at hyperpolarized membrane potentials. Also shows a weak interaction at alpha-3-beta-4/ CHRNA3-CHRNB4 and alpha-7/CHRNA7 nAChRs subtypes. In vivo, exhibits a potent analgesic activity in rat partial sciatic nerve injury and chronic constriction injury models. Expressed by the venom duct. The cysteine framework is I (CC-C-C). Alpha4/7 pattern. Has been suggested to be a promising drug candidate for the treatment of neuropathic pain. Shows a very weak inhibition of tetrodotoxin (TTX)-resistant sodium channels. Does not show activity at TTX-sensitive sodium channels, L- or T-type calcium channels, opioid receptors, TRPV1 and KCNQ1 channels. In vivo, does not exhibit any significant side-effects for spontaneous locomotor activity, cardiac and respiratory function and drug dependence. Belongs to the conotoxin A superfamily. A C-terminal amidation at Cys-63 is suggested by authors, despite the lack of Gly residue at position 64 which should provide the amino group (-NH2).